Based on its recent analysis of the interventional radiology market, Frost & Sullivan recognized Siemens Healthcare with the "2013 North American Frost & Sullivan Award for Company of the Year." Siemens said its technology and product innovation-centered growth strategy has helped it maintain its lead and momentum in market expansion, even during the recent industry-wide slowdown. Its smart innovations, backed by the value they generate at various levels of the care continuum, including clinical care, business enterprise as well as patients, have not only enhanced the standard of care but also offered a myriad of clinical and operational benefits.
“In addition to competing effectively at both ends of the market, Siemens Healthcare can also pride itself on creating entirely new product tiers,” said Frost & Sullivan Industry Principal Nadim Daher. “Siemens has been at the forefront of the early development of hybrid interventional imaging solutions over the last 10 years, with Artis zeego being the first such solution to enter the market in 2007 — more than two years ahead of the competition.”
Siemens widened the scope of interventional imaging with its CT-like rotational angiography three-dimensional (3-D) visualization at the bed side in the in the interventional lab with its syngo DynaCT. Nearly 10 years later, Siemens' DynaCT is still the leader in rotational angiography. Its latest product launches have enhanced all the major product elements of image quality, acquisition speed, and the dose and contrast efficiency in 3-D imaging.
Siemens Healthcare’s new line of premium angiography systems, the Artis Q product line, embodies enhancements such as syngo DynaCT Micro as well as numerous other advances such as Q.zen. In the Q.zen configuration, advances include a newly designed digital crystalline silicon detector that allows better detail visualization at lower radiation dosages. These new systems incorporate Siemens’ second-generation of proprietary X-ray tube flat emitter technology, which also contributes to higher dose efficiency of these systems.
Siemens can be deemed the first vendor to ever bring functional imaging to a clinical setting during interventional procedures. Similar to its hybrid interventional imaging solution, Siemens’ parenchymal blood volume (PBV) technology, syngo DynaPBV, is another industry first. Following its release in 2009 as a breakthrough neurology application for brain imaging (syngo DynaPBV Neuro), the syngo DynaPBV Body applies 3-D functional imaging in a whole new set of interventional radiology procedures.
The highly sophisticated algorithms that constitute the CARE and CLEAR software packages represent another layer of product differentiation for Siemens. The CARE portfolio offers cutting-edge dose reduction, monitoring and reporting techniques, and is delivered to customers as standard — not at added costs — in all of Siemens’ Artis zee, zeego, Q and Q.zen systems.
“As an established interventional radiology vendor of choice in the largest number of university and academic hospitals in the U.S., Siemens Healthcare is best suited to address the needs of newly consolidated hospital networks,” noted Daher. “It is also strategically placed to help in the creation of clinical specialty centers of excellence in cardiology, trauma and oncology.”
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
More information: www.usa.siemens.com/interventional-imaging
July 25, 2024 
